1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
(
- Contribution to journal › Article
- 2019
-
Mark
The association between weight at birth and breast cancer risk revisited using Mendelian randomisation
(
- Contribution to journal › Article
- 2016
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article